Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C
Lancet (London, England) · 1,365 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Cancer Research UK
- Organización sin fines de lucro
- British Heart Foundation
- Gobierno
- Medical Research Council
Según 3 financiadores declarados.
Publicación
- Publicado
- 2008-01-01 · Lancet · vol. 371 · número 9607 · págs. 117–125
- Editorial
- Elsevier BV
- Citado
- 2,084 citas · más que el 100% de estudios similares · 22.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 48 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Cancer, Lipids, and Metabolism
- Palabras clave
- statins, diabetes mellitus, LDL cholesterol lowering, type 1 diabetes, type 2 diabetes, major vascular events, all-cause mortality, vascular death, myocardial infarction, coronary revascularization, stroke, hypercholesterolemia, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke prevention, cardiovascular risk stratification
- MeSH
- humans, cardiovascular diseases, diabetes mellitus, type 1, diabetes mellitus, type 2, triglycerides, hydroxymethylglutaryl-coa reductase inhibitors, middle aged, female, male, cholesterol, ldl, multicenter studies as topic, randomized controlled trials as topic
1 autor
- Cholesterol Treatment Trialists' (CTT) Collaborators🇬🇧 · autor de correspondenciaUniversity of Oxford
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Although statin therapy reduces the risk of occlusive vascular events in people with diabetes mellitus, there is uncertainty about the effects on particular outcomes and whether such effects depend on the type of diabetes, lipid profile, or other factors. We undertook a prospective meta-analysis to help resolve these uncertainties.
Methods
We analysed data from 18 686 individuals with diabetes (1466 with type 1 and 17,220 with type 2) in the context of a further 71,370 without diabetes in 14 randomised trials of statin therapy. Weighted estimates were obtained of effects on clinical outcomes per 1.0 mmol/L reduction in LDL cholesterol.
Findings
During a mean follow-up of 4.3 years, there were 3247 major vascular events in people with diabetes. There was a 9% proportional reduction in all-cause mortality per mmol/L reduction in LDL cholesterol in participants with diabetes (rate ratio [RR] 0.91, 99% CI 0.82-1.01; p=0.02), which was similar to the 13% reduction in those without diabetes (0.87, 0.82-0.92; p<0.0001). This finding reflected a significant reduction in vascular mortality (0.87, 0.76-1.00; p=0.008) and no effect on non-vascular mortality (0.97, 0.82-1.16; p=0.7) in participants with diabetes. There was a significant 21% proportional reduction in major vascular events per mmol/L reduction in LDL cholesterol in people with diabetes (0.79, 0.72-0.86; p<0.0001), which was similar to the effect observed in those without diabetes (0.79, 0.76-0.82; p<0.0001). In diabetic participants there were reductions in myocardial infarction or coronary death (0.78, 0.69-0.87; p<0.0001), coronary revascularisation (0.75, 0.64-0.88; p<0.0001), and stroke (0.79, 0.67-0.93; p=0.0002). Among people with diabetes the proportional effects of statin therapy were similar irrespective of whether there was a prior history of vascular disease and irrespective of other baseline characteristics. After 5 years, 42 (95% CI 30-55) fewer people with diabetes had major vascular events per 1000 allocated statin therapy.
Interpretation
Statin therapy should be considered for all diabetic individuals who are at sufficiently high risk of vascular events.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.